RxDoctor Payments Data

Ramy Doss, MD

Cardiovascular Disease · Phoenix, AZNPI 1629032487

Payments from drug & device makers

$19,206in general payments, 2019–2025

Across 735 payments — averaging $26.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$3K
  • Angiodynamics, Inc.$2K
  • Amgen$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Pfizer$1K
  • Novartis$926
  • plus $10K from 49 others

What the payments were for

  • Consulting fees$370%
  • Travel & lodging$1,7989%
  • Food & beverage$15,11279%
  • Education$5773%
  • Other$1,6819%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,206 in reported general payments places this provider in the 80th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$551,500
Medicare patients
620
Services billed
4,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban307$385,036
Repatha SureclickEvolocumab141$146,082
EntrestoSacubitril/Valsartan92$128,414
CamzyosMavacamten13$92,746
XareltoRivaroxaban34$51,427
Repatha PushtronexEvolocumab39$50,676
VascepaIcosapent Ethyl73$50,278
FarxigaDapagliflozin Propanediol27$29,393
JardianceEmpagliflozin21$23,156
Nebivolol Hcl298$21,475
LivaloPitavastatin Calcium21$20,922
Repatha SyringeEvolocumab17$17,963
OzempicSemaglutide14$16,227
Praluent PenAlirocumab21$12,913
BrilintaTicagrelor12$12,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,006$385,036307 claims
NovartisEntresto$926$128,41492 claims
E.r. Squibb & Sons, L.L.C.Camzyos$437$92,74613 claims
Johnson & JohnsonXarelto$301$51,42734 claims
AstraZenecaFarxiga, Brilinta$357$41,75439 claims
Boehringer IngelheimJardiance$264$23,15621 claims
Kowa Pharmaceuticals America, Inc.Livalo$864$20,92221 claims
Novo NordiskOzempic$678$16,22714 claims
MerckVerquvo$805$8,12812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →